BCAL Diagnostics (ASX:BDX) Other Gross PPE : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Other Gross PPE?

BCAL Diagnostics's Other Gross PPE for the quarter that ended in Dec. 2023 was A$0.00 Mil.

BCAL Diagnostics's quarterly Other Gross PPE increased from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$1.10 Mil) but then declined from Jun. 2023 (A$1.10 Mil) to Dec. 2023 (A$0.00 Mil).

BCAL Diagnostics's annual Other Gross PPE stayed the same from . 20 (A$0.00 Mil) to Jun. 2022 (A$0.00 Mil) but then increased from Jun. 2022 (A$0.00 Mil) to Jun. 2023 (A$1.10 Mil).

BCAL Diagnostics Other Gross PPE Historical Data

The historical data trend for BCAL Diagnostics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Other Gross PPE Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Other Gross PPE

1.10

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Other Gross PPE	Get a 7-Day Free Trial			-	-	-	1.10	-

BCAL Diagnostics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.